Despite in vitro experiments demonstrating the effectiveness of small molecule inhibitors on GBM-specific oncogenic EGFR variants, they have not yielded consistent responses in GBM patients harboring such mutations [17, 18]. The gene discussed is EGFR; the disease is glioblastoma.